0001209191-20-058263.txt : 20201113 0001209191-20-058263.hdr.sgml : 20201113 20201113155351 ACCESSION NUMBER: 0001209191-20-058263 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201112 FILED AS OF DATE: 20201113 DATE AS OF CHANGE: 20201113 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McClellan William D. Jr. CENTRAL INDEX KEY: 0001689402 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37785 FILM NUMBER: 201311299 MAIL ADDRESS: STREET 1: C/O APOLLO ENDOSURGERY, INC., 1120 S. STREET 2: CAPITAL OF TEXAS HWY, BLDG. 1, SUITE 300 CITY: AUSTIN STATE: TX ZIP: 78746 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REATA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001358762 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113651945 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5320 LEGACY DRIVE CITY: PLANO STATE: TX ZIP: 75024 BUSINESS PHONE: 972-865-2219 MAIL ADDRESS: STREET 1: 5320 LEGACY DRIVE CITY: PLANO STATE: TX ZIP: 75024 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-11-12 0 0001358762 REATA PHARMACEUTICALS INC RETA 0001689402 McClellan William D. Jr. 5320 LEGACY DRIVE PLANO TX 75024 1 0 0 0 Class A common stock 2020-11-12 4 C 0 4000 A 4000 D Class A common stock 2020-11-12 4 S 0 2542 172.4384 D 1458 D Class A common stock 2020-11-12 4 S 0 970 173.2148 D 488 D Class A common stock 2020-11-12 4 S 0 488 174.8196 D 0 D Stock Option (right to buy) 25.52 2020-11-12 4 M 0 4000 0.00 D 2027-06-14 Class B common stock 4000 2000 D Class B common stock 2020-11-12 4 M 0 4000 25.52 A Class A common stock 4000 4000 D Class B common stock 2020-11-12 4 C 0 4000 D Class A common stock 4000 0 D The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $171.88 to $172.86. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $172.88 to $173.87. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $173.91 to $174.15. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The options vested in 4 equal installments on September 14, 2017, December 14, 2017, March 14, 2018, and June 14, 2018. /s/ Tracy Herson, attorney-in-fact 2020-11-13